PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era

PURPOSE OF REVIEW: The first monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) have been approved for clinical use. This timely review highlights recent developments. RECENT FINDINGS: Low-density lipoprotein cholesterol (LDL-C) is the primary driver of atheroscler...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Curr Opin Lipidol
Prif Awduron: Chapman, M. John, Stock, Jane K., Ginsberg, Henry N.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2015
Pynciau:
THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. Watts
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4927326/
https://ncbi.nlm.nih.gov/pubmed/26780005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MOL.0000000000000239
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg